skip to Main Content

Attenuated FOLFIRINOX in the Salvage Treatment of Gemcitabine-Refractory Advanced Pancreatic Cancer: a Phase II Study

Newsfeed image, light gray text on dark gray background
Combination therapy with oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) chemotherapy drastically improves survival of advanced pancreatic cancer patients.

However, the efficacy of FOLFIRINOX as a second-line treatment after gemcitabine failure has not been tested prospectively. We investigated the feasibility and safety of attenuated FOLFIRINOX in patients with gemcitabine-refractory advanced pancreatic cancer. Read more . . .

Back To Top